Document is current
Any future updates will be listed below
-
Authors
Mahan, Thomas E.
Wang, Chao
Bao, Xin
Choudhury, Ankit
Ulrich, Jason D.
Holtzman, David M. https://orcid.org/0000-0002-3400-0856
-
Funding
Funding for this research was provided by:
cure alzheimer's fund
jpb foundation
national institute of neurological disorders and stroke (NS090932)
national institute on aging (AG047644)
- License Information
-
More Information
Article History
Received: 16 July 2021
Accepted: 13 January 2022
First Online: 2 February 2022
Declarations
:
: All animal procedures and experiments were performed under guidelines approved by the Institutional Animal Care and Use Committee (IACUC) at Washington University School of Medicine.
: All authors have approved of the manuscript and agreed with its submission.
: D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Denali and consults for Genentech, Merck, and Cajal Neuroscience. All other authors have no competing interests.
